

PRECEPTORSHIP PROGRAMME

Breast Cancer

Multidisciplinary management,
standards of care, therapeutic targets
and future perspectives

**ESMO VIRTUAL
PRECEPTORSHIP**

22-23 NOVEMBER 2021

Co-Chairs

Rebecca A. Dent, Singapore

Peter Schmid, United Kingdom

ESMO VIRTUAL PRECEPTORSHIP PROGRAMME BREAST CANCER

Multidisciplinary management, standards of care, therapeutic targets
and future perspectives

22-23 November 2021

CO-CHAIRS:

Rebecca A. Dent, Singapore
Peter Schmid, United Kingdom

SPEAKERS:

Fabrice André, France	Soo Chin Lee, Singapore
Charlotte Coles, United Kingdom	Shani Paluch-Shimon, Israel
Peter Dubsy, Switzerland	Puay Hoon Tan, Singapore
Seock-Ah Im, Korea	Veronique K. M. Tan, Singapore
Sherko Kümmel, Germany	Janice W.-H. Tsang, Hong Kong

LEARNING OBJECTIVES

- To learn about genetic testing and management of BRCA carriers
- To learn about the biology of breast cancer and its implications in the management of this disease
- To learn about the standard of care management of early, locally advanced, and metastatic breast cancer in surgery, radiation therapy and systemic therapy
- To understand the crucial role of multidisciplinary care in the management of breast cancer

ACCREDITATION

The programme of this event has been accredited with **7 ESMO-MORA category 1 points**.
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For future details, please refer to esmo.org.

ACKNOWLEDGMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org



All timings in the programme are to be considered Singapore local time (GMT+8)

Monday, 22 November 2021

15:00-15:05 5'	Opening and welcome	
5'	Welcome and introduction	Rebecca A. Dent, SG Peter Schmid, UK
15:05-16:00 55'	MODULE 1 Biology	Chair/Moderator:
25'	New breast cancer classification and new technologies: What's relevant in everyday practice?	Puay Hoon Tan, SG
20'	Prognostic and predictive markers for breast cancer management	Sherko KümmeI, DE
10'	Discussion	Faculty
16:00-16:10	Break	
16:10-17:15 65'	MODULE 2 Local-regional treatment	Chair/Moderator:
25'	Principles of breast surgery / oncoplastic surgery	Veronique K. M. Tan, SG
25'	Principles of breast radiation therapy	Charlotte Coles, UK
15'	Discussion	Faculty
17:15-18:20 65'	MODULE 3 Triple Negative Breast Cancer (TNBC)	Chair/Moderator:
25'	(Neo-) adjuvant systemic therapy	Peter Schmid, UK
25'	Systemic therapy for metastatic TNBC	Rebecca A. Dent, SG
15'	Discussion	Faculty
18:20-18:50 30'	MODULE 4 Clinical case discussion and Q&A	Chair/Moderator: Rebecca A. Dent, SG Peter Schmid, UK

Tuesday, 23 November 2021

15:00-16:35 95'	MODULE 5 ER+/HER2 negative breast cancer Luminal BC	Chair/Moderator:
25'	(Neo-) adjuvant endocrine therapy (pre and postmenopausal)	Peter Dubsy, CH
25'	How to select patients in ER+/HER2 negative BC (real practice scenario)	Janice W.-H. Tsang, HK
10'	Discussion	Faculty
25'	ET and targeted therapies for ER+/HER2 negative ABC	Fabrice André, FR
10'	Discussion	Faculty
16:35-16:45	Break	

16:45-17:25 40'	MODULE 6 Hereditary Breast Cancer	Chair/Moderator:
30'	Hereditary breast cancer	Shani Paluch-Shimon, IL
10'	Discussion	Faculty
17:25-18:30 65'	MODULE 7 HER2+ breast cancer	Chair/Moderator:
25'	(Neo-) adjuvant systemic therapy	Soo Chin Lee, SG
25'	Systemic therapy for HER2+ advanced breast cancer	Seock-Ah Im, KR
15'	Discussion	Faculty
18:30-19:00 30'	MODULE 8 Clinical case discussion and Q&A	Chair/Moderator: Rebecca A. Dent, SG Peter Schmid, UK
19:00-19:05 5'	Closing remarks	Rebecca A. Dent, SG Peter Schmid, UK

Note: Each 10-minute slot for clinical case discussion includes 5' case presentation and 5' Q&A / panel discussion